RCUS.US Arcus Biosciences Inc

Healthcare Biotechnology USA Stocks
16.39 USD
Close of Nov 17, 2026
16.33 31.74
Market cap
USD 2.36B
P/E
-
P/B
6.78x
ROE
-129.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RCUS.US undervalued?

Graham number

The Graham number of Arcus Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Arcus Biosciences Inc fundamental analysis

No fundamental analysis for Arcus Biosciences Inc yet.

Arcus Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor…

Full company profile